+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID04322890

Evaluating Treatment Approaches and Survival in Adults with Advanced Non-Small Cell Lung Cancer With Specific Gene Mutations

Led by Hunan Province Tumor Hospital · Updated on 2024-10-22

6000

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating treatment strategies and survival outcomes for people with non-small cell lung cancer NSCLC that have specific genetic changes called oncogenic mutations. This Phase 2 study includes patients with various mutations such as EGFR, ALK, ROS1, RET, BRAF, NRG1, MET, KRAS, and others. The study aims to understand how different mutations affect treatment response and survival. Participants receive targeted drugs based on their specific mutation group. Treatments include Osimertinib for EGFR mutations, Alectinib or Lorlatinib for ALK fusion, Crizotinib for ROS1 fusion, Savolitinib or Crizotinib for MET alterations, and chemotherapy given intravenously every 21 days. The study has several cohorts grouped by mutation type to assess outcomes for each. During the study, participants are monitored for progression-free survival up to 36 months, overall survival up to 5 years, tumor response rates, adverse events, and patient-reported outcomes. Assessments include imaging to measure lesions and evaluations of side effects and quality of life. The study collects data on treatment effectiveness and safety while participants are followed regularly until the study ends or their condition changes.

CONDITIONS

Brief Title

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Research Team

Y

Yongchang Zhang, MD

N

Nong Yang, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here